12月11日，中国证监会发布《关于湖南鸣鸣很忙商业连锁股份有限公司境外发行上市及境内未上市股 份"全流通"备案通知书》，鸣鸣很忙上市备案已获通过。该公司拟发行不超过76,666,400股境外上市普 通股并在香港联合交易所上市，25名股东拟将所持合计198,079,551股境内未上市股份转为境外上市股 份，并在香港联合交易所上市流通。据悉，2025年4月28日，鸣鸣很忙首次向港交所主板递交上市申 请，2025年10月28日，公司更新上市申请材料，继续推进上市进程。 ...

Core Viewpoint - The article discusses the rapid growth and challenges faced by Wancheng Biological, particularly its "Haoxianglai" brand, which has expanded to over 15,000 stores but is burdened by high debt and operational risks due to increased competition and extended payback periods for franchisees [2][3][4][5]. Financial Performance - Wancheng Biological's revenue surged from 5.49 billion yuan in 2022 to 323.29 billion yuan by mid-2025, with a significant increase in the share of snack and beverage retail business from 12.1% in 2022 to 98.9% in 2025 [6]. - The adjusted net profit showed a dramatic increase, reaching approximately 9.22 billion yuan in the first half of 2025, reflecting a growth rate of 287.39% year-on-year [8]. - Despite high revenue growth, the net profit margin has declined significantly, with a net profit margin of only 3.85% in the first half of 2025, compared to historical levels of around 10% to 20% from 2018 to 2021 [8]. Expansion Strategy - The company has aggressively expanded its franchise network, growing from 160 franchise stores in 2022 to 15,300 by mid-2025, with over 99% of its stores being franchises [6][7]. - Wancheng Biological's debt has increased dramatically, with current liabilities rising from approximately 3.32 billion yuan at the end of 2022 to 51.28 billion yuan by the end of 2024 [10]. Market Position - "Haoxianglai" has become the leading brand in the snack retail sector, holding a market share of 0.91%, while the top five brands collectively hold only about 3.85% of the market [20]. - The competitive landscape is characterized by a duopoly between Wancheng Biological and Mingming Group, with both companies vying for market share in a fragmented industry [21]. Operational Challenges - Franchisees are facing increased operational challenges, with the payback period for opening a "Haoxianglai" store extending from about one year to three years due to rising costs and market saturation [9][15]. - The company has reported significant increases in inventory levels, which could pose risks to its operations if not managed effectively [16]. Leadership and Governance - The founder of Wancheng Biological, Wang Jiankun, is under investigation, leading to concerns about governance and stability within the company [17][18]. - Wang Zening, the founder's son, has taken on a more prominent role in the company, which may influence its strategic direction moving forward [18][19].